Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
| ▸ | HTR5A | P47898 | 2/20 | 0.34 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2262579 | 0.98 | HTR2A (0.42) | HTR2AHTR2CKDM1AHTR2BWEE1 | |
| SCHEMBL28981462 | 0.82 | HTR2C (0.39) | HTR2AHTR2CKDM1AHTR2BDPP4 | |
| SCHEMBL25246576 | 0.79 | KDM1A (0.39) | HTR2AHTR2CKDM1AHTR5ASRD5A1 | |
| SCHEMBL30496380 | 0.78 | KDM1A (0.41) | HTR2AHTR2CKDM1AHTR5ASRD5A1 | |
| SCHEMBL25591142 | 0.78 | PNMT (0.46) | HTR2AHTR2CKDM1AHTR2B | |
| SCHEMBL3178174 | 0.78 | MRGPRX2 (0.46) | HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL30098020 | 0.76 | PNMT (0.44) | HTR2AHTR2CKDM1AHTR2B | |
| Bromide SCHEMBL7682620 | 0.76 | MRGPRX2 (0.45) | HTR2AHTR2C | |
| SCHEMBL2258910 | 0.76 | CYP1A2 (0.40) | HTR2AHTR2CHTR5APGRAKR1B1 | |
| SCHEMBL3177100 | 0.75 | KCNH2 (0.43) | HTR2AHTR2CHTR2BHTR5ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225223-B1 | ORGANIC COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-11 | — | — | EP | disclosed |
| EP-2225223-B1 | ORGANIC COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-11 | — | — | EP | disclosed |
| US-20110195954-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| US-20110195954-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| EP-2251338-A2 | Organic compounds | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2251338-A2 | Organic compounds | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2225223-A2 | ORGANIC COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009065919-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009065919-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195954-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | HTR2A 426/4885HTR2C 546/4885KDM1A 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.